Hoth Therapeutics announces promising preclinical results for Alzheimer's drug HT-ALZ

Initial observations suggest that vehicle-treated Alzheimer mice have a larger population of reactive astrocytes, while HT-ALZ-treated groups show fewer reactive astrocytes, suggesting a potential breakthrough in the treatment of Alzheimer's disease.

NEW YORK, 17 September 2024 /PRNewswire/ — Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing innovative treatments for unmet medical needs, today announced encouraging preclinical results for its investigational drug. Alzheimer's drugHT-ALZ. In a recent study using Alzheimer model mice treated with different doses of HT-ALZ, significant reductions in astrocyte activity were observed in key areas of the brain, suggesting a possible link between reduced reactive astrocytes and improved cognitive function.

The study examined the effect of different doses of aprepitant on the hippocampus and cerebral cortex by astrocyte staining. The data showed a significant decrease in the percentage of area covered by astrocytes in the hippocampus at both 20 mg and 40 mg compared to the vehicle-treated group. A similar trend was observed in the cerebral cortex. This reduction in reactive astrocytes was associated with improved cognitive performance in the same dose groups, further suggesting that the therapeutic benefit of aprepitant may be related to its effect on astrocytic activity.

Reactive astrocytes, which are typically larger than normal astrocytes, play a role in the development of neurodegenerative diseases such as Alzheimer's. Hoth Therapeutics is currently conducting a secondary analysis to determine if the size or total number of astrocytes is changed by treatment. Initial observations suggest that the vehicle-treated Alzheimer's mice have a larger population of reactive astrocytes, while the HT-ALZ-treated groups have fewer reactive astrocytes, suggesting a potential breakthrough in the treatment of Alzheimer's.

Robb KnieCEO of Hoth Therapeutics, stated: “These preclinical results are a promising step forward in our mission to develop effective therapies for Alzheimer's disease. The reduction in astrocyte activity and the corresponding improvements in cognitive functions observed with HT-ALZ give us confidence to move forward in our development process.”

Hoth Therapeutics plans to advance HT-ALZ through further studies and clinical trials to provide a new therapeutic option for patients with Alzheimer's disease. For more information on HT-ALZ and Hoth's innovative pipeline, please visit our website.

About Hoth Therapeutics, Inc.

Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful and breakthrough treatments with the goal of improving the quality of life for patients. We are a catalyst in early-stage pharmaceutical research and development, moving drugs from the laboratory into preclinical and clinical testing. Using a patient-centric approach, we collaborate with a team of scientists, clinicians and key opinion leaders to seek and investigate therapeutics that have tremendous potential to deliver breakthroughs and diversify treatment options. For more information, visit

Forward-looking statements

This press release contains forward-looking statements based on Hoth's current expectations that may constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws and are subject to significant risks, uncertainties and assumptions. These statements concern Hoth's business strategies; the timing of regulatory filings; the ability to obtain and maintain regulatory approval for existing and any other product candidates we develop, and labeling under any approval we receive; the timing and cost of clinical trials and the timing and cost of other expenditures; the market acceptance of our products; the ultimate impact of the current coronavirus pandemic or other health epidemic on our business, clinical trials, research programs, healthcare systems or the global economy as a whole; our intellectual property; our dependence on third party organizations; our competitive position; our industry environment; our expected financial and operating results, including expected revenue streams; our assumptions regarding the size of the available market, the benefits of our products, product pricing and the timing of product launches; management's expectations regarding future acquisitions; statements regarding our objectives, intentions, plans and expectations, including the introduction of new products and markets; and our cash requirements and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated in such forward-looking statements. You should not rely on these forward-looking statements, which contain words such as “may,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “may,” “continue,” “predict,” “potential,” “project” or similar terms, variations of such terms, or the negative of such terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such results. Hoth may not meet its expectations and its beliefs may prove to be incorrect. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, but not limited to, market conditions and the factors described in the “Risk Factors” section of Hoth's most recent Annual Report on Form 10-K and Hoth's other filings with the Securities and Exchange Commission. All such statements speak only as of the date they are made. Accordingly, forward-looking statements should be considered only as Hoth's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth can provide no guarantees of future results, events, levels of activity, performance or achievements. Hoth undertakes no obligation, and expressly disclaims any obligation, to update, republish or revise any forward-looking statements to reflect new information, future events or circumstances or the occurrence of unanticipated events, except as required by law.

Contact for investors:
LR Advisors LLC
E-mail: [email protected]
www.hoththerapeutics.com
Phone: (678) 570-6791

Never miss a story from Hoth Therapeutics, Inc.